Intersect ENT Inc (XENT) Releases Earnings Results, Beats Expectations By $0.05 EPS

Intersect ENT Inc (XENT) reported quarterly earnings results on Tuesday, Aug-2-2016. The company said it had a profit of $-0.21 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.05. Analysts had a consensus of $-0.26. The company posted revenue of $19.30 million in the period, compared to analysts expectations of $19.29 million. The company’s revenue was up 27.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.23 EPS.

Intersect ENT Inc opened for trading at $15.65 and hit $15.941 on the upside on Friday, eventually ending the session at $15.84, with a gain of 1.21% or 0.19 points. The heightened volatility saw the trading volume jump to 1,95,008 shares. Company has a market cap of $449 M.

In a different news, on Jul 19, 2016, James Stambaugh (VP Clinical Affairs) sold 5,000 shares at $15.33 per share price. According to the SEC, on Apr 28, 2016, Amy Wolbeck (V.P. Regulatory Affairs & Qlty) sold 2,000 shares at $20.01 per share price. On Apr 22, 2016, Richard E Kaufman (Sr VP& Chief Operating Officer) sold 3,603 shares at $18.85 per share price, according to the Form-4 filing with the securities and exchange commission.

Intersect ENT Inc. is a commercial-stage drug-device company. The Company develops drugs for patients with ear nose and throat conditions. The Company’s commercial products are the PROPEL and PROPEL mini drug-eluting implants for patients undergoing sinus surgery to treat chronic sinusitis. The Company is also developing PROPEL mini for use in frontal sinus surgery and is conducting clinical trials to evaluate two products RESOLVE and NOVA for treatment of patients in the physician’s office. The Company is developing the RESOLVE steroid releasing implant as an alternative treatment option for patients who are candidates for revision surgery that can be placed in the physician office setting during a routine visit. The Company is also developing NOVA a steroid releasing implant designed to fit the openings of the frontal and maxillary sinuses following ostial dilation using balloon sinuplasty.

Intersect ENT Inc

Leave a Reply

Intersect ENT Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Intersect ENT Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.